Using the same dataset, we further evaluated lung cancer patients with known mutations in EGFR, KRAS, and ALK. Lung cancer patients with EGFR and/or KRAS mutations were found to have higher SALL4 expression, while patients with ALK mutations did not have significantly higher SALL4 expression (Supplementary Figure S2). Here, ALK is linked to lung carcinoma.